Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

Treatment outcomes for older patients with acute myeloid leukemia (AML) have remained dismal. This randomized, phase 2 trial in AML patients not considered suitable for intensive induction therapy compared low-dose cytarabine (LDAC) with or without volasertib, a highly potent and selective inhibitor...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Döhner, Hartmut, Lübbert, Michael, Fiedler, Walter, Fouillard, Loic, Haaland, Alf, Brandwein, Joseph M., Lepretre, Stephane, Reman, Oumedaly, Turlure, Pascal, Ottmann, Oliver G., Müller-Tidow, Carsten, Krämer, Alwin, Raffoux, Emmanuel, Döhner, Konstanze, Schlenk, Richard F., Voss, Florian, Taube, Tillmann, Fritsch, Holger, Maertens, Johan
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2014
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4148765/
https://ncbi.nlm.nih.gov/pubmed/25006120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-03-560557
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares